Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses

References:

1. 1.↵
   ICH Harmonized Tripartite Guideline. Specifications: Test Procedures and Acceptance Criteria for Biotechological/Biological Products, Q6B, ICH Steering Committee, 10 March 1999.
2. 2.↵
   ICH Harmonized Tripartite Guideline. Quality Risk Management, Q9, Current Step 4 version, dated 9 November 2005.
3. 3.↵
   1. Cogdill R. P.,
   2. Drennen J. K.

   Risk-based quality by design (QbD): a Taguchi perspective on the assessment of product quality, and the quantitative lingkage of drug product parameters and clinical performance. J. Pharm Innov, 2008, 3 (1), 23–29.

   OpenUrl
4. 4.↵
   1. Tharmalingham T.,
   2. Gheheh H.,
   3. Wuerz T.,
   4. Butler M.

   Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol. Biotechnol. 2008, 39 (2), 167–177.

   OpenUrlPubMed
5. 5.↵
   1. outledge S. J.,
   2. Hewitt C. J.,
   3. Bora N.,
   4. Bill R. M.

   Antifoam addition to shake flask cultures ofrecombinant Pichia pastoris increases yield. Micro. Cell Fact. 2011, 10, 1–11.

   OpenUrl
6. 6.↵
   1. Nema S.,
   2. Brendel R. J.

   Current usage and future directions excipients and their role in approved injectable products. PDA J. Pharm. Sci Technol. 2011, 65 (3), 287–332.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Powell M. F.,
   2. Nguyen T.,
   3. Baloian L.

   Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 238–311.

   OpenUrlFREE Full Text
8. 8.↵
   1. Rowe R.,
   2. Sheskey P. J.,
   3. Cook W. G.,
   4. Fenton M. E.

   Handbook of Pharmaceutical Excipients, 7th ed.; Rowe R., Sheskey P. J., Cook W. G., Fenton M. E. Eds.; Pharmaceutical Press: London, 2012.
9. 9.↵
   1. Kasper D.,
   2. Braunwald E.,
   3. Hauser S.,
   4. Longo D.,
   5. Jameson L.,
   6. Fauci A.

   1. Howard L.

   Enteral and Parenteral Nutrition Therapy. In Harrison's Principles of Internal Medicine, 16th ed.; Kasper D., Braunwald E., Hauser S., Longo D., Jameson L., Fauci A. Eds.; McGraw-Hill: New York, 2005; pp 415–422.
10. 10.↵
    ICH Consensus Guideline. Guideline for elemental impurities, Q3D, Current Step 4 version dated 16 December 2014.
11. 11.↵
    U.S. Food and Drug Administration, Center for Drug Evaluation and Research (FDA-CDER). Inactive Ingredient Search for Approved Drug Products, 2014.
12. 12.↵
    Food and Drugs: Substances Generally Recognized as Safe. Code of Federal Regulations, Title 21, Part 182, Volume 3, Revised as of April 1, 2013.
13. 13.↵
    ICH Harmonized Tripartite Guideline. Impurities: Guideline for Residual Solvents, Q3C (R5), 2011.
14. 14.↵
    ICH Consensus Guideline. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7. Current Step 4 version dated 23 June 2014.
15. 15.↵
    ICH Harmonised Tripartite Guideline. Nonclinical Evaluation for Anticancer Pharmaceuticals, S9, Current Step 4 version dated 29 October 2009.
16. 16.↵
    1. Zhao X.,
    2. Lin H.,
    3. Qiu J.

    Reagent Clearance Capability of Protein A Chromatography: A Platform Strategy for Elimination of Process Reagent Clearance Testing. Bioprocess Int. 2015, 13 (5), 1–8.

    OpenUrl
17. 17.↵
    1. Fahrner R.L.,
    2. Knudsen H.L.,
    3. Basey C.D.,
    4. Galan W.,
    5. Feuerhelm D.,
    6. Vanderlaan M.

    Industrial purification of pharmaceutical antibodies: development, operation and validation of chromatography processes. biotechnol. Genet. Eng. Rev., 2001, 18, 301–327.

    OpenUrlPubMed
18. 18.↵
    1. Follman D.,
    2. Fahrner R. L.

    Factorial screening of antibody purification processes using three chromatographic steps without Protein A. J. Chromatogr. A, 2004, 1024 (1), 79–85.

    OpenUrlPubMed
19. 19.↵
    1. Fuglistaller P.

    Comparison of immunoglobulin binding capacities and ligand leakage using eight different protein A affinity chromatography matrices. J. Immunol. Methods 1989, 124 (2), 171–177.

    OpenUrlPubMed
20. 20.↵
    FDA. Guidance for Industry: Process Validation: General Principles and Practices, 2013.
21. 21.↵
    FDA, Center for Biologics Evaluation and Research. Points To Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. February 28, 1997.
22. 22.↵
    The European Agency for Evaluation of Medicinal Products. Note for guidance on virus validation studies: the design, contribution, and interpretation of studies validating the inactivation and removal of viruses, cpmp/bwp/268/95, February 11, 1996.